SSMXY Quote, Financials, Valuation and Earnings

Healios KK has a net margin of 13.36% compared to Sysmex's net margin of -6742.11%. Sysmex's return on equity of 11.69% beat Healios KK's return on equity of -196.15%.

Sysmex has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Sysmex has higher upside potential than Healios KK, analysts believe Sysmex is more attractive than Healios KK.

Sysmex has a beta of 1.131, which suggesting that the stock is 13.059% more volatile than S&P 500. In comparison Healios KK has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Sysmex has a quarterly dividend of $0.12 per share corresponding to a yield of 1.31%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sysmex pays 33.69% of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend. Sysmex's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sysmex quarterly revenues are $815.5M, which are larger than Healios KK quarterly revenues of $249.2K. Sysmex's net income of $108.9M is higher than Healios KK's net income of -$16.8M. Notably, Sysmex's price-to-earnings ratio is 29.18x while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sysmex is 3.08x versus 83.05x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.

PeptiDream has a net margin of 13.36% compared to Sysmex's net margin of -24.41%. Sysmex's return on equity of 11.69% beat PeptiDream's return on equity of 34.1%.

Sysmex has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream has an analysts' consensus of -- which suggests that it could fall by --. Given that Sysmex has higher upside potential than PeptiDream, analysts believe Sysmex is more attractive than PeptiDream.

Sysmex has a beta of 1.131, which suggesting that the stock is 13.059% more volatile than S&P 500. In comparison PeptiDream has a beta of 0.523, suggesting its less volatile than the S&P 500 by 47.679%.

Sysmex has a quarterly dividend of $0.12 per share corresponding to a yield of 1.31%. PeptiDream offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sysmex pays 33.69% of its earnings as a dividend. PeptiDream pays out -- of its earnings as a dividend. Sysmex's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sysmex quarterly revenues are $815.5M, which are larger than PeptiDream quarterly revenues of $27.8M. Sysmex's net income of $108.9M is higher than PeptiDream's net income of -$6.8M. Notably, Sysmex's price-to-earnings ratio is 29.18x while PeptiDream's PE ratio is 14.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sysmex is 3.08x versus 4.93x for PeptiDream. Usually stocks with elevated PS ratios are considered overvalued.

Nxera Pharma has a net margin of 13.36% compared to Sysmex's net margin of -11.44%. Sysmex's return on equity of 11.69% beat Nxera Pharma's return on equity of -8.65%.

Sysmex has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Sysmex has higher upside potential than Nxera Pharma, analysts believe Sysmex is more attractive than Nxera Pharma.

Sysmex has a beta of 1.131, which suggesting that the stock is 13.059% more volatile than S&P 500. In comparison Nxera Pharma has a beta of 0.374, suggesting its less volatile than the S&P 500 by 62.646%.

Sysmex has a quarterly dividend of $0.12 per share corresponding to a yield of 1.31%. Nxera Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sysmex pays 33.69% of its earnings as a dividend. Nxera Pharma pays out -- of its earnings as a dividend. Sysmex's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sysmex quarterly revenues are $815.5M, which are larger than Nxera Pharma quarterly revenues of $43.6M. Sysmex's net income of $108.9M is higher than Nxera Pharma's net income of -$5M. Notably, Sysmex's price-to-earnings ratio is 29.18x while Nxera Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sysmex is 3.08x versus 2.85x for Nxera Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Takeda Pharmaceutical has a net margin of 13.36% compared to Sysmex's net margin of -9.79%. Sysmex's return on equity of 11.69% beat Takeda Pharmaceutical's return on equity of 1.49%.

Sysmex has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical has an analysts' consensus of $17.00 which suggests that it could grow by 15.46%. Given that Takeda Pharmaceutical has higher upside potential than Sysmex, analysts believe Takeda Pharmaceutical is more attractive than Sysmex.

Sysmex has a beta of 1.131, which suggesting that the stock is 13.059% more volatile than S&P 500. In comparison Takeda Pharmaceutical has a beta of 0.223, suggesting its less volatile than the S&P 500 by 77.69%.

Sysmex has a quarterly dividend of $0.12 per share corresponding to a yield of 1.31%. Takeda Pharmaceutical offers a yield of 4.52% to investors and pays a quarterly dividend of $0.34 per share. Sysmex pays 33.69% of its earnings as a dividend. Takeda Pharmaceutical pays out 280.28% of its earnings as a dividend. Sysmex's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Takeda Pharmaceutical's is not.

Sysmex quarterly revenues are $815.5M, which are smaller than Takeda Pharmaceutical quarterly revenues of $6.9B. Sysmex's net income of $108.9M is higher than Takeda Pharmaceutical's net income of -$676.5M. Notably, Sysmex's price-to-earnings ratio is 29.18x while Takeda Pharmaceutical's PE ratio is 67.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sysmex is 3.08x versus 1.57x for Takeda Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.